Clinical trials: Cancer Liver, open to volunteers
Hepatocellular Carcinoma, Beyond Milan Criteria
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
Surgical resection is the primary curative treatment for patients with hepatocellular carcinoma (HCC), with a 5-year overall survival rate of 60-80% post-surgery.
- Trial name
- NCT06467799
- Testing
- Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
HCC, Hepatocellular Carcinoma
Y-90 Treatment Response Using Transarterial Radioembolization
This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE).
- Conditions
- HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm
- Trial name
- TARE (NCT07145801)
- Testing
- Lumason, Sonazoid
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Jefferson University
Hepatocellular Carcinoma
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with…
- Trial name
- NCT05620771
- Testing
- Y90 + Atezolizumab and Bevacizumab, Y90 + TKI
- Where
- 7 sites in United States
- Volunteers
- 200 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma (HCC)
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome
The goal of this interventional study (clinical trial) is to evaluate the efficacy and safety of adding dapagliflozin to first-line standard therapy in patients with unresectable hepatocellular carcinoma (HCC) and comorbid…
- Trial name
- NCT07729592
- Testing
- Dapagliflozin, Donafenib, Tislelizumab
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Colorectal Cancer, Liver Metastases
Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research
The patients with non-resectable colorectal liver metastases (CRLM) have always being considered a particular subgroup of CRLM in which the therapeutic approach, is focused on strategies that allow a potential surgery like…
- Conditions
- Colorectal Cancer, Liver Metastases, Genetic Change
- Trial name
- NCT05398380
- Testing
- Liver transplantation
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Hospital Vall d'Hebron
Liver Metastases From Colorectal Cancer
Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
This study is an investigator-initiated, randomized controlled trial enrolling patients with colorectal liver metastases. The objectives are to evaluate the safety and efficacy of contrast-enhanced ultrasound (CEUS)-mediated…
- Trial name
- CEUSON (NCT07365527)
- Testing
- Low-intensity contrast enhanced ultrasound, High-intensity contrast enhanced ultrasound
- Where
- 2 sites in Denmark
- Volunteers
- 48 people
- Sponsor
- Zealand University Hospital
HCC - Hepatocellular Carcinoma, Conversion Therapy
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
Conversion therapy for unresectable intermediate-advanced hepatocellular carcinoma (uHCC) has evolved from systemic therapy to combined local-systemic approaches, but current regimens still have limited surgical conversion rates.
- Trial name
- NCT07560488
- Testing
- Bevacizumab Biosimilar IBI305, ipilimumab N01, Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Tumor, Gastric Cancer
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Gastric Cancer, Liver Cancer
- Trial name
- NCT06873659
- Testing
- SON-DP
- Where
- 11 sites in China
- Volunteers
- 96 people
- Sponsor
- Qurgen Inc.
Hepatocellular Carcinoma (HCC), Metastasis
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
This study will evaluate whether resection of the primary liver tumor, in addition to standard first-line systemic therapy, improves survival in patients with hepatocellular carcinoma that has spread outside the liver but still…
- Trial name
- NCT07537959
- Testing
- Primary Tumor Resection, Protocol-Allowed First-Line Immune-Based Systemic Therapy
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to…
- Trial name
- ARTEMIDE-HCC01 (NCT06921785)
- Testing
- Tremelimumab, Rilvegostomig, Bevacizumab
- Where
- 226 sites in United States, Australia and 18 more
- Volunteers
- 1,220 people
- Sponsor
- AstraZeneca
HCC - Hepatocellular Carcinoma
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD).
- Trial name
- ABATE-MASLD (NCT07285850)
- Testing
- Sequential treatment of bevacizumab combined with atezolizumab (sequential group), Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Uveal Melanoma
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with…
- Trial name
- NCT07364474
- Testing
- Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Hepatitis B, Hepatocellular Carcinoma (HCC)
TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma
Study Objective: To compare the efficacy and prognosis of systemic cancer therapy between TAF monotherapy and ETV plus TAF combination therapy in patients with unresectable, advanced hepatitis-B-related hepatocellular carcinoma…
- Trial name
- NCT07253220
- Testing
- The arm will receive combination therapy (entecavir 0.5 mg once daily plus TAF 25 mg once daily); after HBV DNA becomes undetectable, the combination group will switch to TAF monotherapy., TAF monotherapy
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Post-Hepatectomy Liver Failure, Liver Failure
CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure
Removing a large part of the liver (major hepatectomy) can cure primary and secondary liver cancers, but it carries the risk of post-hepatectomy liver failure (PHLF), a serious complication in which the liver left behind - the…
- Conditions
- Post-Hepatectomy Liver Failure, Liver Failure, Liver Neoplasms, Carcinoma, Hepatocellular
- Trial name
- BEYOND-SIZE (NCT07727759)
- Testing
- Preoperative CT volumetry with hepatic vascular deformation mapping (VDM)
- Where
- 3 sites in Egypt
- Volunteers
- 1,070 people
- Sponsor
- Minia University
Colorectal Cancer, Liver Metastases
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing…
- Trial name
- SPARKLE-L (NCT06794086)
- Testing
- Stereotactic body radiation therapy, PD-1 Monoclonal Antibody, Chemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jun Huang
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma
- Trial name
- NCT07405086
- Testing
- Biospecimen Collection, Immune Checkpoint Inhibitor
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- OHSU Knight Cancer Institute
Liver Cancer
The Application Value of Spectral CT in the Accurate Staging of Liver Cancer
Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the application value in the accurate…
- Trial name
- NCT06977399
- Testing
- To explore the value of spectral CT in the diagnosis and treatment of liver cancer
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Yunnan Cancer Hospital
HCC - Hepatocellular Carcinoma, Immunotherapy
Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals
This study aims to evaluate the response to immunotherapy in HCC, assess the toxicity profile and measure overall survival within the study period.
- Conditions
- HCC - Hepatocellular Carcinoma, Immunotherapy, Immune Checkpoint Therapy, Immune Checkpoint Inhibitor-Induced Dermatitis
- Trial name
- NCT07088081
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.